EA201892010A1 - Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию - Google Patents
Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессиюInfo
- Publication number
- EA201892010A1 EA201892010A1 EA201892010A EA201892010A EA201892010A1 EA 201892010 A1 EA201892010 A1 EA 201892010A1 EA 201892010 A EA201892010 A EA 201892010A EA 201892010 A EA201892010 A EA 201892010A EA 201892010 A1 EA201892010 A1 EA 201892010A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- locuses
- enhanced expression
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028555 WO2017184832A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892010A1 true EA201892010A1 (ru) | 2019-03-29 |
Family
ID=58701851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892010A EA201892010A1 (ru) | 2016-04-20 | 2017-04-20 | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (enExample) |
| EP (1) | EP3445781A1 (enExample) |
| JP (4) | JP7096770B2 (enExample) |
| KR (3) | KR102906454B1 (enExample) |
| CN (2) | CN109195986B (enExample) |
| AR (1) | AR109451A1 (enExample) |
| AU (2) | AU2017253241B2 (enExample) |
| BR (1) | BR112018071283A2 (enExample) |
| CA (1) | CA3015389A1 (enExample) |
| EA (1) | EA201892010A1 (enExample) |
| IL (2) | IL262266B2 (enExample) |
| MX (2) | MX2018012868A (enExample) |
| SG (2) | SG10202010155YA (enExample) |
| TW (2) | TW202415767A (enExample) |
| WO (1) | WO2017184832A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012868A (es) | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| CN113631711B (zh) * | 2018-12-21 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| EP3950938A4 (en) * | 2019-04-02 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN |
| AU2020308002A1 (en) * | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| US20230304062A1 (en) | 2021-10-18 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Controlled transcription of polynucleotides |
| US12234472B2 (en) | 2021-10-18 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| TW202334402A (zh) | 2021-10-18 | 2023-09-01 | 美商再生元醫藥公司 | 包含整合ｃａｓ９基因以產生穩定整合位點的哺乳動物細胞，以及包含穩定整合位點及其他位點的哺乳動物細胞 |
| EP4453227A1 (en) * | 2021-12-22 | 2024-10-30 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| US20250361524A1 (en) * | 2022-06-10 | 2025-11-27 | Fujifilm Diosynth Biotechnologies Uk Limited | Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool |
| CN121794393A (zh) | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2026050618A1 (en) | 2024-08-29 | 2026-03-05 | Regeneron Pharmaceuticals, Inc. | Polynucleotide constructs and cell lines for recombinant aav production |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| AU2003237259B2 (en) | 2002-05-29 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| CA2504595A1 (en) | 2002-11-14 | 2004-06-03 | Lynne Krummen | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| WO2008151219A1 (en) * | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8409838B2 (en) * | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| CN102575264A (zh) | 2009-09-18 | 2012-07-11 | 瑟莱克斯公司 | 增加的转基因表达和加工的产品和方法 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN104011080B (zh) | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TW202423993A (zh) | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2017005306A (es) * | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
| KR102777500B1 (ko) | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| MX2018012868A (es) * | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
-
2017
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en not_active Ceased
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 IL IL262266A patent/IL262266B2/en unknown
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt active Search and Examination
- 2017-04-20 KR KR1020237020953A patent/KR102906454B1/ko active Active
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active Active
- 2017-04-20 KR KR1020257043281A patent/KR20260011194A/ko active Pending
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
-
2018
- 2018-10-19 MX MX2025003852A patent/MX2025003852A/es unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US12528883B2/en active Active
-
2023
- 2023-11-29 JP JP2023201924A patent/JP7781128B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
-
2025
- 2025-10-08 JP JP2025170326A patent/JP2025188169A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892137A1 (ru) | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию | |
| BR112018071283A2 (pt) | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. | |
| JOP20210071A1 (ar) | أجسام مضادة مثبّتة trem2 | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
| PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| AR121002A2 (es) | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica | |
| CL2019002310A1 (es) | Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797) | |
| AR115963A1 (es) | Anticuerpos anti-il1rap y métodos de uso de estos | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
| SA521420953B1 (ar) | بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1 | |
| EA201892693A1 (ru) | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 | |
| MY200337A (en) | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain | |
| AR103867A1 (es) | Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| CR20210225A (es) | RECEPTORES DE ANTÍGENES QUIMÉRICOS BASADOS EN ANTICUERPOS DE DOMINIO SIMPLE Y MÉTODOS DE USO DE ESTOS (Divisional 2018-0153) | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA201691795A1 (ru) | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| MX380702B (es) | Proteinas de union al antigeno del receptor de oncostatina m. |